Issues Associated With the Case Report Entitled “Hypertensive Urgency Associated With Xenadrine EFX Use”

Moaddeb J Tofade TS Bevins MB. Hypertension urgency associated with Xenadrine EFX use. [published online ahead of print June 6 2011]. J Pharm Pract; 2011. doi: 10.1177/0897190011406127

Anon. Iovate group of companies acquired xenadrine, cytodyne, taraxatone, and related brands. http://www.getbig.com/headlines/2008/04/15/iovate-group-of-companies-acquires-xenedrine-cytodyne-taraxatone-and-related-brand-names/. Accessed April 2008.

Chen JK Chen TT. Ma Huang (Herba Ephedra). Chinese Medical Herbology and Pharmacology. City of Industry, CA: Art of Medicine Press; 2004:36–40.

Stohs SJ Preuss HG. The safety of bitter orange (Citrus aurantium) and its primary protoalkaloid p-synephrine. HerbalGram. 2011;89:34–39.

Stohs SJ Preuss HG Shara M. The safety of Citrus aurantium (bitter orange) and its primary protoalkaloid p-synephrine [published online ahead of print April 8 2011]. Phytother Res. 2011. doi:10.1002/ptr.3490.

Seifert JG Nelson A Devonish J Burke ER Stohs SJ. Effect of acute administration of an herbal preparation on blood pressure and heart rate in humans. Int J Med Sci. 2011;8(3):192–197.

Stohs SJ Preuss HG Keith SC Keith PL Miller H Kaats GR. Effects of p-synephrine alone and in combination with selected bioflavonoids on resting metabolism, blood pressure, heart rate and self-reported mood changes. Int J Med Sci. 2011;8(4):295–301.

Stohs SJ Preuss HG Shara M. A review of the receptor binding properties of p-synephrine as related to its pharmacological properties. Oxid Med Cell Long. 2011. In press.

Mercader J Wanecq E Chen J Carpene C. Isopropylnorsynephrine is a stronger lipolytic agent in human adipocytes than synephrine and other amines present in. Citrus aurantium. J Physiol Biochem. 2011;67(3):443–52. doi:10.1007/s13105-011-0078-2.

Stohs SJ Preuss HG Shara M. A review of the human clinical studies of bitter orange (Citrus aurantium) extract and its primary protoalkaloid p-synephrine. TANG. 2011. doi: 10.1155/2011/482973.

Gurley BJ Gardner SF Hubbard MA . In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther. 2004;76(5):428–440.

Stohs SJ . Assessment of the adverse event reports associated with. Citrus aurantium (bitter orange) from April 2004 to October 2009. J Funct Foods. 2010;2:235–238.

McGuffin M. Media spins numbers on bitter orange AERs based on erroneous information from FDA. HerbalGram. 2006;69:52–55.

Dietary Supplement Health and Education Act of 1994. http://www.healthy.net/public/legallg/fedregs/S784_ENR.HTM

Dietary supplement current good manufacturing practices (cGMPs) and interim final rule (IFR) facts. www.fda.gov/Food/DietarySupplementsGuidanceComplianceRegulatoryInformation/RegulatoryLaws/ucm979573.htm. Accessed June, 2007.

Haller CA Benowitz NL Peyton J III. Hemodynamic effects of ephedra-free weight loss supplements in humans. Am J Med. 2005;118(9):998–1003.

Dragull K Breksa AP Cain B. Synephrine content of juice from Satsuma mandarins (Citrus unshiu Marcovitch). J Agr Food Chem. 2008;56(19):8874–8878.

Uckoo RM Jayaprakasha GK Nelson DS Patil BS. Rapid simultaneous determinations of amines and organic acids in citrus using high-performance liquid chromatography. Talanta. 2010;83(3):948–954.

Karch SB. Peer review and the process of publishing of adverse drug event reports. J Forensic Leg Med. 2007;14(2):79–84.